Brentuximab is a biosimilar directed against the extracellular domain of CD30. The brentuximab antibody selectively targets tumor cells expressing the cell membrane protein CD30 and delivers the MMAE, which causes apoptosis by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic microtuble network, thereby preventing tumor growth and proliferation.
